UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv238-iv255

2018

Volltextzugriff (PDF)

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Oncogene, 2013-10, Vol.32 (41), p.4861-4870

2013

Volltextzugriff (PDF)

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2019-05, Vol.30 (5), p.871-873

2019

Volltextzugriff (PDF)

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

Alimentary pharmacology & therapeutics, 2006-06, Vol.23 (11), p.1535-1547

2006

Volltextzugriff (PDF)

Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

Hepatology (Baltimore, Md.), 1999-12, Vol.30 (6), p.1434-1440

1999

Volltextzugriff (PDF)

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Hepatology (Baltimore, Md.), 2003-02, Vol.37 (2), p.429-442

2003

Volltextzugriff (PDF)

Hepatocellular carcinoma

The Lancet (British edition), 2003-12, Vol.362 (9399), p.1907-1917

2003

Volltextzugriff (PDF)

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Gut, 2002-01, Vol.50 (1), p.123-128

2002

Volltextzugriff (PDF)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128

2018

Volltextzugriff (PDF)

New molecular therapies for hepatocellular carcinoma

Clinics and research in hepatology and gastroenterology, 2015-09, Vol.39, p.S80-S85

2015

Volltextzugriff (PDF)

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

ESMO open, 2023-06, Vol.8 (3), p.101567-101567, Article 101567

2023

Volltextzugriff (PDF)

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Annals of oncology, 2022-06, Vol.33 (6), p.666-666

2022

Volltextzugriff (PDF)

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2001-05, Vol.33 (5), p.1124-1129

2001

Volltextzugriff (PDF)

New aspects of diagnosis and therapy of hepatocellular carcinoma

Oncogene, 2006-06, Vol.25 (27), p.3848-3856

2006

Volltextzugriff (PDF)

Post-fire hydrological and erosional responses of a Mediterranean landscpe: Seven years of catchment-scale dynamics

Catena (Giessen), 2007-09, Vol.71 (1), p.68-75

2007

Volltextzugriff (PDF)

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Annals of oncology, 2022-09, Vol.33, p.S1401

2022

Volltextzugriff (PDF)

Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials

Hepatology (Baltimore, Md.), 1999-01, Vol.29 (1), p.62-67

1999

Volltextzugriff (PDF)

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Seminars in liver disease, 1999, Vol.19 (3), p.329-338

1999

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of oncology, 2018-10, Vol.29, p.viii208-viii208

2018

Volltextzugriff (PDF)

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1578-1583

1998

Volltextzugriff (PDF)

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Annals of oncology, 2021-06, Vol.32 (6), p.801-805

2021

Volltextzugriff (PDF)

Next-Generation Sequencing: Path for Driver Discovery in Hepatocellular Carcinoma

Gastroenterology (New York, N.Y. 1943), 2012-11, Vol.143 (5), p.1391-1393

2012

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2018-06, Vol.29, p.v122-v122

2018

Volltextzugriff (PDF)

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2000-01, Vol.31 (1), p.54-58

2000

Volltextzugriff (PDF)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2019-07, Vol.30, p.iv133-iv133

2019

Volltextzugriff (PDF)

1 – 25 von 478

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(396)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(207)
Humans
(198)
Life Sciences & Biomedicine
(179)
Male
(108)
Female
(94)
Gastroenterology & Hepatology
(82)
Middle Aged
(80)
Biological And Medical Sciences
(73)
Medical Sciences
(67)
Adult
(57)
Aged
(55)
Hepatocellular Carcinoma
(43)
Tumors
(42)
Oncology
(38)
Prognosis
(38)
Gastroenterology And Hepatology
(37)
Carcinoma, Hepatocellular - Therapy
(35)
Liver Neoplasms - Pathology
(34)
Liver Neoplasms - Therapy
(34)
Gastroenterology. Liver. Pancreas. Abdomen
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Hepatocellular carcinoma

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

New molecular therapies for hepatocellular carcinoma

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma

New aspects of diagnosis and therapy of hepatocellular carcinoma

Post-fire hydrological and erosional responses of a Mediterranean landscpe: Seven years of catchment-scale dynamics

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Next-Generation Sequencing: Path for Driver Discovery in Hepatocellular Carcinoma

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Aktive Filter

Suchergebnisse filtern